Pardes Biosciences, Inc. (PRDS)

NASDAQ: PRDS · IEX Real-Time Price · USD
1.92
-0.09 (-4.73%)
Feb 3, 2023, 4:00 PM EST - Market closed
-4.73%
Market Cap 118.22M
Revenue (ttm) n/a
Net Income (ttm) -107.38M
Shares Out 61.73M
EPS (ttm) -11.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,692
Open 2.00
Previous Close 2.01
Day's Range 1.87 - 2.00
52-Week Range 0.75 - 13.01
Beta n/a
Analysts Buy
Price Target 10.54 (+450.39%)
Earnings Date n/a

About PRDS

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 63
Stock Exchange NASDAQ
Ticker Symbol PRDS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PRDS stock is "Buy." The 12-month stock price forecast is $10.54, which is an increase of 450.39% from the latest price.

Price Target
$10.54
(450.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acti...

4 days ago - GlobeNewsWire

RM LAW Announces Investigation of Pardes Biosciences, Inc.

BERWYN, Pa. , Jan. 30, 2023 /PRNewswire/ --  RM LAW, P.C.

5 days ago - PRNewsWire

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

BOSTON--(BUSINESS WIRE)--Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Came...

Other symbols: ASMB
2 weeks ago - Business Wire

Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023 Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected...

3 months ago - GlobeNewsWire

Pardes Biosciences to Present at Jefferies London Healthcare Conference

CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acti...

3 months ago - GlobeNewsWire

Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C.

CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral anti...

5 months ago - GlobeNewsWire

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo

5 months ago - GlobeNewsWire

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-ac...

5 months ago - GlobeNewsWire

Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CARLSBAD, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug can...

6 months ago - GlobeNewsWire

Pardes Biosciences to Present at Jefferies Global Healthcare Conference

CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acti...

8 months ago - GlobeNewsWire

Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-actin...

9 months ago - GlobeNewsWire

Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update

CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-act...

11 months ago - GlobeNewsWire

Pardes Biosciences to Present at the International Conference On Antiviral Research 2022

CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acti...

11 months ago - GlobeNewsWire

Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-actin...

1 year ago - GlobeNewsWire

Pardes Biosciences to Present at Cowen Healthcare Conference

CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-actin...

1 year ago - GlobeNewsWire

Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board

Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be bene...

1 year ago - GlobeNewsWire

Pardes Biosciences Shares Early Data From COVID-19 Study

Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Conference on Retroviruses and Opportunistic Infections (C...

1 year ago - Benzinga

Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022

PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2

1 year ago - GlobeNewsWire

Pardes Biosciences to Host Virtual Investor Event

Company to host conference call and webcast at 3 p.m. PT on Tuesday, February 15, 2022 Company to host conference call and webcast at 3 p.m. PT on Tuesday, February 15, 2022

1 year ago - GlobeNewsWire

Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022

CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral ant...

1 year ago - GlobeNewsWire

Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19

The FDA has signed off Pardes Biosciences Inc's PRDS Investigational New Drug (IND) application for PBI-0451 for COVID-19. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

1 year ago - Benzinga

Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections

CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral ant...

1 year ago - GlobeNewsWire

Pardes Biosciences to Present at J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral ant...

1 year ago - GlobeNewsWire

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19

1 year ago - GlobeNewsWire

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

SAN FRANCISCO & LARKSPUR, Calif.--(BUSINESS WIRE)--FSII and Pardes Biosciences move towards merger with the goal of tackling COVID-19 via an oral antiviral.

1 year ago - Business Wire